Older adults with resectable gastric cancer undergoing perioperative chemotherapy or preoperative chemoradiotherapy plus perioperative chemotherapy: A secondary analysis of the AGITG TOPGEAR phase III trial
European Journal of Cancer · 2026
DOI: 10.1016/j.ejca.2026.117005 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift European Journal of Cancer, 2026. Verfasst von Alexander Rühle und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, University of Leipzig Medical Center, Comprehensive Cancer Center Central Germany, Leipzig, Germany; Radiation Medi…. Hauptthemen laut MEDLINE: Stomach Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Adenocarcinoma, Neoadjuvant Therapy. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Canadian Institutes of Health Research, Cancer Australia, Health Research Council of New Zealand.
Abstract (Originalsprache)
PURPOSE: To evaluate treatment adherence, adverse events, and survival in older (≥70 years) adults undergoing perioperative treatment for gastric cancer. METHODS: Patients with resectable gastric/gastro-esophageal junction adenocarcinoma (ECOG 0-1) enrolled in the phase III TOPGEAR trial were randomized to perioperative chemotherapy (ECF/ECX or FLOT) alone or perioperative chemotherapy plus preoperative chemoradiotherapy (45 Gy in 25 fractions with concurrent fluoropyrimidine). In this exploratory analysis, treatment completion, grade ≥ 3 adverse events (CTCAE v3.0), surgical outcomes, overall survival (OS) and progression-free survival (PFS) were compared between older and younger adults. RESULTS: Of the 574 patients enrolled, 135 (24%) were ≥ 70 years. Older adults more frequently required preoperative chemotherapy dose reductions, omissions, or delays (chemoradiotherapy: 55% vs 35%, p = 0.004; chemotherapy: 60% vs 48%, p = 0.087). Rates of grade ≥ 3 adverse events were comparable between older and younger patients (chemoradiotherapy: 66% vs 67%, p = 0.874; chemotherapy: 68% vs 59%, p = 0.220), but older adults more often had hematologic toxicity and grade ≥ 3 diarrhea in the chemotherapy group (56% vs 37%, p = 0.006; 21% vs 6%, p < 0.001). Resection rates, grade 3/4 surgical complications, number of removed lymph nodes, and 30-/90-day mortality were similar by age. OS and PFS were comparable across age groups, with numerically favorable outcomes for older adults (OS: HR 0.86, 95% CI 0.58-1.26 [chemoradiotherapy]; HR 0.75, 95% CI 0.51-1.11 [chemotherapy]; PFS: HR 0.78, 95% CI 0.53-1.15 [chemoradiotherapy]; HR 0.70, 95% CI 0.47-1.03 [chemotherapy]). CONCLUSIONS: Older adults with gastric cancer achieved comparable oncologic outcomes to younger patients, despite more frequent treatment modifications and higher hematologic toxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, University of Leipzig Medical Center, Comprehensive Cancer Center Central Germany, Leipzig, Germany; Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, Canada; Depart…
- Department of Medicine II, University of Leipzig Medical Center, Leipzig, Comprehensive Cancer Center Central Germany, Leipzig, Germany; Department of Oncology and University Cancer Center Leipzig (UCCL), University of…
- National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia. Electronic address: rachel.oconnell@sydney.edu.au.
- National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia. Electronic address: john.simes@sydney.edu.au.
- Department of Medical Oncology, Peter MacCallum Cancer Centre, and the Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia. Electronic address: michael.michael@petermac.org.
- Division of Surgery, Princess Alexandra Hospital, University of Queensland, Brisbane, Australia. Electronic address: m.smithers@uq.edu.au.
Förderung
- Canadian Institutes of Health Research
- Cancer Australia
- Health Research Council of New Zealand
- National Health and Medical Research Council
- European Organisation for Research and Treatment of Cancer
- Canadian Cancer Society Research Institute
Zitieren
APA
Rühle, A., Krause, A., O'Connell, R. L., Simes, J., Michael, M., Smithers, B. M., Wong, R. K. S., Haustermans, K., Nicolay, N. H., Leong, T., & Lordick, F. (2026). Older adults with resectable gastric cancer undergoing perioperative chemotherapy or preoperative chemoradiotherapy plus perioperative chemotherapy: A secondary analysis of the AGITG TOPGEAR phase III trial. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2026.117005
Vancouver
Rühle A, Krause A, O'Connell RL, Simes J, Michael M, Smithers BM, et al. Older adults with resectable gastric cancer undergoing perioperative chemotherapy or preoperative chemoradiotherapy plus perioperative chemotherapy: A secondary analysis of the AGITG TOPGEAR phase III trial. European Journal of Cancer. 2026. doi:10.1016/j.ejca.2026.117005
BibTeX
@article{Rhle2026,
author = {Rühle, Alexander and Krause, Alina and O'Connell, Rachel L and Simes, John and Michael, Michael and Smithers, Bernard Mark and Wong, Rebecca K S and Haustermans, Karin and Nicolay, Nils H and Leong, Trevor and Lordick, Florian},
title = {Older adults with resectable gastric cancer undergoing perioperative chemotherapy or preoperative chemoradiotherapy plus perioperative chemotherapy: A secondary analysis of the AGITG TOPGEAR phase III trial},
journal = {European Journal of Cancer},
year = {2026},
doi = {10.1016/j.ejca.2026.117005}
}
EUVIMED